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Hromadová D, Lo JW, Neves JF,
Howard JK, Helmby H, Powell N,
Strobl B and Lord GM (2021) T-Bet
Controls Cellularity of Intestinal




published: 02 February 2021
doi: 10.3389/fimmu.2020.623324T-Bet Controls Cellularity of
Intestinal Group 3 Innate
Lymphoid Cells
Jan-Hendrik Schroeder1, Katrin Meissl2, Dominika Hromadová2, Jonathan W. Lo1,3,
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Innate lymphoid cells (ILC) play a significant immunological role at mucosal surfaces such
as the intestine. T-bet-expressing group 1 innate lymphoid cells (ILC1) are believed to play
a substantial role in inflammatory bowel disease (IBD). However, a role of T-bet-negative
ILC3 in driving colitis has also been suggested in mouse models questioning T-bet as a
critical factor for IBD. We report here that T-bet deficient mice had a greater cellularity of
NKp46-negative ILC3 correlating with enhanced expression of RORgt and IL-7R, but
independent of signaling through STAT1 or STAT4. We observed enhanced neutrophilia
in the colonic lamina propria (cLP) of these animals, however, we did not detect a greater
risk of T-bet-deficient mice to develop spontaneous colitis. Furthermore, by utilizing an in
vivo fate-mapping approach, we identified a population of T-bet-positive precursors in
NKp46-negative ILC3s. These data suggest that T-bet controls ILC3 cellularity, but does
do not drive a pathogenic role of ILC3 in mice with a conventional specific pathogen-
free microbiota.
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CD127+ innate lymphoid cells (ILC) have been categorized into subsets based on expression of
characteristic transcription factors (1). ILC1 express T-bet (encoded by Tbx21). ILC2 express
GATA3 while ILC3 have a characteristic expression of RORgt. The ILC3 group has three members
depending on the expression of NKp46 and CCR6. NKp46+ ILC3 express T-bet, and CCR6- NKp46-
ILC3 have been suggested to be the precursors of these cells (2). In contrast CCR6+ ILC3 do not
express T-bet and are generated following a developmental pathway that is very distinct to the other
ILC (3).
There is evidence associating IBD and colitis with T-bet-expressing cells alike ILC1. We have
recently reported that enhanced functionality of T-bet variants among individuals is associated withorg February 2021 | Volume 11 | Article 6233241
Schroeder et al. T-Bet Restrains NKp46-Negative ILC3 CellularityCrohn’s disease and ulcerative colitis (4). Furthermore, IFNg
appears to be the most critical factor driving colitis while IL-17A
and IL-13 play a less important role (5–8). Interestingly, these
observations are corroborated by the observation that ILC1 are
particularly abundant among the total amount of ILC in
inflamed intestinal lamina propria of Crohn’s disease patients
(9–11). Furthermore, the generation of ILC1 from an NKp46+
ILC3 source has been linked to colitis development (12). We
have recently observed that NKp46-dependent deletion of Tbx21
in mice leads to milder dextran sodium sulphate (DSS)-induced
colitis, and this may be caused by the depletion of T-bet
expressing ILC1 and ILC3 (13).
However, in contrast to these data supporting a critical
pathogenic role of T-bet+ ILC in colitis, we have also reported
previously that germline depletion of Tbx21 in Rag-deficient
BALB/c-background mice can trigger spontaneous colitis in the
presence of and depending onHelicobacter thyphlonius as part of
the microbiota. In these mice an elevated frequency of
colitogenic IL-17A+ CD90+ CD127+ ILC within the lamina
propria appeared to be the driving force of the pathological
phenotype. A pathogenic role of ILC3 in colitis has also been
suggested by others in mouse models with H. hepaticus and anti-
CD40 antibody driven colitis and even IBD patients (7, 14, 15).
Furthermore, CCR6+ ILC3 have been linked to enhanced airway
hyperreactivity in an obesity model (16). In contrast to these
pathogenic roles of ILC3, several studies highlight their
protective functionality in the intestine [(17–26) reviewed by
(27)]. As such ILC3 were reported to be a critical source of
protective IL-22 early during infection with Citrobacter
rodentium, and depletion of CD4+ CCR6+ ILC3 using an anti-
CD4 antibody led to diminished IL-22 production and enhanced
bacterial tissue infiltration (28, 29).
Hence, in immunocompetent patients, T-bet has the potential
to be a potent drug target to control Crohn’s disease and
ulcerative colitis, but it needs to be established whether this
approach leads to an enhanced pathogenic role of ILC3.
Encouragingly, Tbx21 deficient mice on a BALB/c background
do not develop spontaneous colitis (30). We have also reported
previously that T-bet germline depletion in C57BL/6-
background mice leads to an enhanced cellularity and
functionality of ILC2 which may have a beneficial role to
protect from colitis with a T-bet targeting treatment (13).
In this study, we report that Tbx21 deficiency leads to greater
cellularity of intestinal NKp46-negative ILC3 in Rag-sufficient
and deficient mice. Interestingly, Tbx21 deficiency in these cells
caused enhanced expression of IL-7R and RORgt which may play
a mechanistic role in driving a greater ILC3 cellularity in
immunocompetent mice. In contrast, signaling events via
STAT1 and STAT4 were not critically important to drive the
enhanced cellularity of T-bet-negative ILC3. Despite the greater
ILC3 cellularity, Tbx21-deficient mice did not develop
spontaneous colitis. We believe this work highlights the critical
role of T-bet to restrain ILC3 and neutrophil cellularity in the
colonic lamina propria and provides critical insight into the
feasibility of drug-based targeting of T-bet as therapeutic strategy
for colitis.Frontiers in Immunology | www.frontiersin.org 2METHODS
Animals
C57BL/6, Tbx21-/- (C57BL/6 background), Rag2-/- (BALB/c
background), and Il27RA-/- (C57BL/6 background) mice were
sourced commercially (all Charles River). Ifng-/- (C57BL/6
background) mice were a gift from Dr Anne O’Garra (The
Francis Crick Institute, London). A colony of colitis-free
TRnUC mice was generated from a descendant of the TRUC
colony described previously (31). Stat1-/- (B6.129P2-
Stat1tm1Dlv) (32) and Stat4-/- (C57BL/6J-Stat4em3Adiuj/J,
purchased from The Jackson Laboratory) mice were housed
under specific pathogen-free conditions according to
Federation of European Laboratory Animal Science
Associations (FELASA) guidelines. C57BL/6N and C57BL/6J
mice were purchased from Janvier Labs and used as control
mice for Stat1-/- and Stat4-/- mice respectively. Rosa26YFP/+
(Jackson labs) mice were sourced commercially and bred with
T-betcre/+ mice to generate the T-betCre/+xRosa26YFP/+ (T-
betFM) mice.
Generation of T-betcre/+ Mouse
To allow the expression of the Cre-recombinase under the
expression of the T-bet endogenous promoter, a T-bet knock-
in mouse was generated (GenOway, France). For this purpose, an
IRES-Cre cassette was introduced downstream of the Stop codon
of the T-bet gene, in the 3’UTR (Figure 2A). The genomic region
of interest containing the murine Tbx21 locus was isolated by
PCR from 129Sv genetic background. PCR fragments were
subcloned into the pCR4-TOPO vector (Invitrogen). The
genomic clones (containing intron 1 to exon 6) were used to
construct the targeting vector. Briefly, a 5.6-kb fragment
comprising Tbx21 exon 2 and 6 and a 1.6-kb fragment located
downstream of the Tbx21 exon 6 STOP codon were used to flank
an IRES-Cre cassette (FRT site-PGK promoter-Neo cDNA-
FRT site).
Screening of T-Bet–Targeted Embryonic Stem Cell Clones
The FseI-linearized targeting vector was transfected into C57BL/
6 ES cells. Positive selection was started 48 h after
electroporation, by addition of 200 mg/ml G418 (150 mg/ml
active component; Life Technologies). Then, 275 resistant
clones were isolated, amplified, and screened by PCR and
further confirmed by Southern blot.
Generation of Chimeric Mice and Breeding Scheme
One floxed mutated Tbx21 ES cell clone was microinjected into
albino C57BL/6 strain (C57BL/6J-Tyrc-2J/J) blastocysts, and
gave rise to male chimeras with a significant ES cell
contribution (as determined by the percentage of light and
dark patches on their coat). After mating with C57BL/6 CMV-
Flp–expressing female mice to remove the FRT-flanked Neo
cassette, offspring were genotyped by PCR and Southern blot to
ensure removal of the Neo cassette. PCR and Southern blot
screening conditions are available on request. The mosaic excised
F1 mouse was mated with C57BL/6 WT mice to obtain a pure
line of Cre-expressing T-bet knock-in mice: T-betcre/+.February 2021 | Volume 11 | Article 623324
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cLP and Peyer’s patch-free SI LP leukocytes were isolated using a
published method (33). Briefly, the epithelium was removed by
incubation in HBSS lacking Mg2+ or Ca2+ (Invitrogen)
supplemented with EDTA and HEPES. The tissue was further
digested in HBSS lacking Mg2+ or Ca2+ supplemented with 2%
foetal calf serum (FCS Gold, PAA Laboratories), 0.5 mg/ml
collagenase D, 10 mg/ml DNase I, and 1.5 mg/ml dispase II (all
Roche). The LP lymphocyte-enriched population was harvested
from a 40–80% Percoll (GE Healthcare) gradient interface. For
neutrophil analyses leukocytes were not purified by Percoll
gradient centrifugation.
Flow Cytometry
Flow cytometry was performed using a standard protocol. For
ILC analyses a lineage cocktail of antibodies specific for CD3,
CD45R, CD19, CD11b, TER-119, Gr-1, CD5, and FcϵRI was
used. For a complete list of the antibodies used see Table 1.
LIVE/DEADTM stain (ThermoFisher Scientific Inc.) was used to
determine cell viability. A FoxP3 staining kit (ebioscience) was
used for intracellular staining of transcription factors and
cytokines. In case of cytokine analysis, cells were pre-
stimulated with 100 ng/ml PMA and 2 µM ionomycin in the
presence of 6 µM monensin for 3–4 h prior to flow cytometry
analysis. Samples were acquired using an LSRFortessa™ cell
analyser (Becton Dickinson, USA) or a Cytoflex LX™ for the
data on Stat1-/- and Stat4-/- mice. All the data were analyzed
using FlowJo software (Tree Star, USA). Cell counts were
determined using a fixed amount of inclusion beads
(Spherotec, Inc.) as a reference in the flow cytometry tubes.Frontiers in Immunology | www.frontiersin.org 3In Vivo Murine Faecal Microbiota
Transplant Treatment
Faecal content extracted from the caecum of TRUCmice (31, 34)
was reconstituted in sterile PBS 25% glycerol prior to storage at
-80°C. Mice were orally gavaged with 200 ml aliquots of this
faecal solution and sacrificed after 3 weeks.
Statistics
Results are expressed as mean ± SEM. Data were analyzed using
Student’s t-test or Mann-Whitney U test, as appropriate, using
GraphPad Prism 5.0 (GraphPad Inc., USA). ns: non-significant;
*p < 0.05; **p < 0.01; ***p <0.001; ****p <0.0001.
Study Approval
Animal experiments were performed in accredited facilities in
accordance with the UK Animals (Scientific Procedures) Act
1986 (Home Office Licence Numbers PPL: 70/6792, 70/8127,
and 70/7869). Mice for studies on STAT1 and STAT4 were bred
at the animal facility of the Institute of Animal Breeding and
Genetics, University of Veterinary Medicine Vienna according
to the guidelines of the Federal Ministry of Science, Research
and Economy section 8ff of the Animal Science and
Experiments Act, Tierversuchsgesetz [TVG], BMWF-68.205/
0068-WF/V/3b/2015.RESULTS
T-Bet Control ILC3 Cellularity
We have reported that immunocompetent Tbx21-deficient mice
do not develop spontaneous colitis (30). Tbx21-deficient mice
lack ILC1 and NKp46+ ILC3, hence, we addressed the
functionality of NKp46- ILC3, which may also have a
pathogenic role in colitis. For these analyses we define ILC as
live CD45+ Lin- CD127+ leukocytes (Figure 1A). Surprisingly,
we detected an approximate 3-fold greater population of cLP
NKp46-negative ILC3 in Tbx21-/- C57BL/6 mice in comparison
to wild type (WT) mice (Figures 1B, C). Within this NKp46-
ILC3 population, there is a greater cellularity of NKp46-CCR6-
(double-negative) ILC3, but no significant difference in the
cellularity of CCR6+ ILC3. Non-colitic Rag2-/-xTbx21-/-
(TRnUC) mice also showed an enhanced cellularity of cLP
NKp46- ILC3 with a greater abundance of both NKp46- CCR6-
and CCR6+ ILC3 (Figures 1D, E). Similar to cLP ILC3, there was
a greater cellularity of small intestinal (SI) LP NKp46- ILC3 in
TRnUC mice and among these, the CCR6+ ILC3 population size
was increased significantly (Supplementary Figures 1A, B). For
these analyses, TRnUC mice on a BALB/c background were
chosen because Rag2-/-xTbx21-/- mice on this background appear
to be more prone to colitis than C57BL/6 background Rag2-/-
xTbx21-/- mice (35). Overall, these observations support the
notion that T-bet controls the cellularity of NKp46- ILC3.
Enhanced cellularity of NKp46- CCR6- ILC3 in Tbx21-
deficient mice supported a previous report indicating that these
cells are the precursors of NKp46+ ILC3 (2). Hence, the lack of T-
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Schroeder et al. T-Bet Restrains NKp46-Negative ILC3 Cellularityaccumulation of NKp46- CCR6- ILC3. An interlinkage of
NKp46+ ILC3 and NKp46- CCR6- ILC3 was also highlighted
in another study reporting that NKp46+ ILC3 can lose NKp46
expression (36). In order to detect NKp46- CCR6- ILC3 with a
history of T-bet expression, we generated a mouse model thatFrontiers in Immunology | www.frontiersin.org 4expresses Cre-recombinase under the expression of the Tbx21
endogenous promoter by inserting an IRES-Cre cassette
downstream of the Tbx21 stop codon (Figure 2A). This T-
betCre mouse was then bred to the Rosa26-lox-stop-lox YFP
mouse (Rosa26YFP/+) (37) to generate the T-betCre/+xRosa26YFP/+A
B C
D E
FIGURE 1 | T-bet controls cellularity of intestinal NKp46- ILC3 cLP. ILC of untreated mice were isolated for flow cytometry analysis. (A) ILC were gated as live
CD45+ Lin- CD127+ leukocytes. (B) NKp46-, CCR6+ and double-negative ILC3 in C57BL/6 and C57BL/6-background Tbx21-/- mice were analyzed as live CD45+
Lin- CD127+ RORgt+ leukocytes. (C) Cell number fold change and counts per colon of total NKp46-negative ILC3 and percentage from RORgt+ ILC and counts per
colon of NKp46- CCR6- and CCR6+ ILC3 are shown. (D) NKp46-, CCR6+ and double-negative cLP ILC3 from Rag2-/- and TRnUC mice were analyzed as live
CD45+ Lin- CD127+ RORgt+ leukocytes. (E) Cell number fold change and counts per colon of total NKp46-negative ILC3 and percentage of CCR6+ and NKp46-
CCR6- ILC3 from RORgt+ ILC are shown. Data shown are representative of a minimum of 7 (B, C) or 4 (D, E) biological replicates.February 2021 | Volume 11 | Article 623324
Schroeder et al. T-Bet Restrains NKp46-Negative ILC3 Cellularityfate-mapper mouse (T-betFM). As expected, cLP ILC1 defined as
NKp46+NK1.1+T-bet+ were found to be T-bet fate mapper
positive (T-betFM+) (Figure 2B), confirming the functionality
of the model as these cells have previously been shown to express
T-bet. Interestingly, T-betFM+ NKp46- SI LP ILC3 were detected
supporting the notion that these cells have potential to express
this transcription factor (Figure 2C).
To further evaluate the ILC3 phenotype, we analyzed the
cytokine profiles of CD127+ ILC in Tbx21-/- and WT mice. As
expected CD127+ ILC from Tbx21-/- mice produced very low
amounts of IFNg, but surprisingly there was no altered
expression of IL-17A on a per cell basis in the same mice
(Figures 3A, B). However, due to the greater cellularity of
CD127+ ILC in the intestine of mice lacking T-bet (13) we
anticipate more ILC expressing IL-17A. Hence, we aimed to
investigate whether T-bet also controls the cellularity of cLP
neutrophils (Figures 3C, D). In line with the greater cellularity of
NKp46- ILC3 in Tbx21-/- mice, there was indeed a greater
neutrophilia in these mice. These neutrophils had an unaltered
level of CD11b expression and granularity measured as SSC-A
(Figure 3E) indicating that these neutrophils were not activated.Frontiers in Immunology | www.frontiersin.org 5We aimed to determine whether these neutrophils can be
activated with a pathogenic microbiota. In order to test this
Tbx21-/- mice received an oral gauvage injection of fecal microbes
derived from colitic Rag2-/-xTbx21-/- (TRUC) mice (31, 34).
These Tbx21-/- mice did not show weight abnormalities during
the course of 3 weeks upon fecal microbial transplant (FMT) in
comparison to Tbx21-/- control mice (Figure 3F). Furthermore,
the mass of colon and spleen did not show a significant difference
due to FMT 3 weeks after the treatment (Figure 3G). FMT did
also not result in altered cLP neutrophilia or cLP neutrophil
activation detected by CD11b expression and granularity at this
time point (Figures 3H, I). Hence, Tbx21-/- mice appeared to be
resilient to spontaneous colitis driven by the pathogenic
microbes used.
We have shown that untreated Tbx21-/- mice have a greater
cellularity and activation of ILC2 (13). Hence, IL-5-producing
ILC2 may promote an immune response counteracting to a more
pathogenic response driven by ILC3 in naïve Tbx21-deficient
mice (13). To explore this further we analyzed cLP eosinophilia
in Tbx21-/- mice, but detected no significant difference to WT
mice (Supplementary Figure 2).A
B C
FIGURE 2 | NKp46- ILC3 have fate mapper expression of T-bet. Intestinal lamina propria ILC were isolated for flow cytometry analysis. (A) See method section for
further details on the design. (B) T-betFM and T-bet expression in live CD45+ Lin- CD127+ NKp46+ NK1.1+ cLP ILC and (C) T-betFM expression in live CD45+ Lin-
CD127+ NKp46+ and NKp46- SI LP ILC3 are illustrated. Data shown are representative of one experiment (B) or 2 (C) replicates.February 2021 | Volume 11 | Article 623324









FIGURE 3 | T-bet deficiency promotes intestinal neutrophilia. Leukocytes were isolated from the colonic lamina propria of untreated WT and Tbx21-/- mice for flow
cytometry analysis. (A, B) IL-17A and IFNg expression in live CD45+ Lin- CD127+ CD90.2+ leukocytes after a 4 h stimulation with PMA and ionomycin was analyzed
and statistical analyses are shown. (C, D) CD11b+ Gr1+ Ly6C+ F4/80- neutrophils were analyzed from a live CD45+ cLP leukocyte population and neutrophil counts
per colon are shown. (E) CD11b geometric median fluorescence intensity (gMFI) and granularity (SSC-A gMFI) were determined for WT and Tbx21-/- cLP neutrophils.
(F–I) Tbx21-/- mice received a fecal transplant with pathogenic microbes derived from TRUC mice (31). (F) Changes in body weights were monitored on a weekly
basis in Tbx21-/- mice upon FMT and Tbx21-/- control mice. Colon and spleen mass (G) and cLP neutrophil cellularity (H) were determined 3 weeks upon FMT
treatment. (I) CD11b gMFI and SSC-A gMFI in cLP neutrophils 3 weeks upon FMT treatment are illustrated. Data shown are representative of 3 biological replicates.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 6233246




FIGURE 4 | T-bet deficiency promotes RORgt and CD127 expression by cLP ILC3. ILC were isolated from the colonic lamina propria of C57BL/6 and
C57BL/6-background Tbx21-/-, and BALB/c-background Rag2-/- and TRnUC mice for flow cytometry analysis of RORgt and CD127 expression. RORgt
gMFI expression in total NKp46-, CCR6+ and double-negative ILC3 from (A) WT and Tbx21-/- and (B) Rag2-/- and TRnUC mice was analyzed within the live
CD45+ Lin- CD127+ RORgt+ leukocyte population. (C) CD127 surface expression in total NKp46-negative ILC3 and ILC2 defined as KLRG1+ ICOS+ CD127+
ILC is illustrated with flow cytometry histograms. Statistical analyses of CD127 surface expression (gMFI) on total NKp46-, CCR6+ and double-negative ILC3
and ILC2 from (D) WT and Tbx21-/- and (E) Rag2-/- mice are presented. Data shown are representative of a minimum of 7 (A–D) or 4 (E) biological
replicates.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 6233247
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Enhanced Expression of RORgt and CD127
Strikingly, the finding of enhanced cellularity of NKp46- ILC3 in
Tbx21-/- mice correlated with enhanced RORgt expression in
total NKp46- CCR6- ILC3, but not in CCR6+ ILC3 (Figure 4A).
In contrast, in TRnUC mice RORgt expression was only
enhanced in SI LP NKp46- CCR6- ILC3, but not SI LP CCR6+
ILC3 or cLP ILC3 (Supplementary Figure 3, Figure 4B).
Previously, we have also reported that Tbx21 deficiency
causes greater expression of the a chain of IL-7R (CD127) on
total CD127+ ILC in the intestine (13). In the current study we
can now pinpoint that within this Tbx21-deficient population
cLP NKp46- CCR6- ILC3, but not CCR6+ ILC3 or ILC2 express
more CD127 (Figures 4C, D). This was again in contrast to
TRnUC mice as cLP and SI LP ILC3 and ILC2 in these mice did
not display an altered CD127 expression in comparison to
Rag2-/- mice (Figure 4E, Supplementary Figures 3B, C).
Mechanistically, we have reported previously that T-bet binds
to the Cd127 locus in Th1 cells polarized in vitro (31, 38). Hence,
it appears that T-bet is a regulator of Cd127 and Rorc (encoding
RORgt) expression at the transcriptional level which may be
factors limiting the cellularity of NKp46- CCR6- ILC3 in Rag-
sufficient mice.Frontiers in Immunology | www.frontiersin.org 8Mice Deficient in IFNg, IL-27Ra, STAT1, or
STAT4 Have Unaltered Cellularity of
NKp46- ILC3
We further aimed to identify mediators upstream of T-bet that
may be involved in limiting the cellularity of NKp46- ILC3.
Surprisingly, there was no alteration in the cellularity of NKp46-
CCR6- and CCR6+ cLP ILC3 and no change in RORgt and
CD127 expression in ILC3 derived from STAT1 (Stat1-/-) or
STAT4 (Stat4-/-) deficient mice (Figure 5A, Supplementary
Figures 4C, D). This observation was confirmed by the
analysis of the same parameters in those ILC3 from mice
deficient of IFNg (Ifng-/-) or IL-27Ra (Il27RA-/-), both of
which cause signaling events through STAT1 (Supplementary
Figures 4A–D). Furthermore, the absence of STAT4 but not
STAT1 in the germline did result in significantly altered IL-17A
expression in CD127+ CD90.2+ cLP ILC (Supplementary
Figures 4E, F).
T-bet-deficient mice have a greater cellularity of cLP ILC2
(13). In order to correlate with these data, we analyzed ILC2
abundance in Stat1-/- and Stat4-/- mice. As observed with
NKp46-negative ILC3, the cellularity of cLP ILC2 did not alter
in mice deficient of either STAT1 or STAT4 and CD127
expression levels in these cells did also not change (Figure 5B,A
B
FIGURE 5 | STAT1 and STAT4 deficiency does not promote ILC3 cellularity. cLP ILC were isolated from mice for flow cytometry analysis. Counts per colons of (A)
NKp46-CCR6- and CCR6+ ILC3 and (B) ILC2 in WT, Stat1-/- and Stat4-/- mice are shown. Data shown are representative of 4 biological replicates.February 2021 | Volume 11 | Article 623324
Schroeder et al. T-Bet Restrains NKp46-Negative ILC3 CellularitySupplementary Figure 5A). Furthermore, CD127 expression
was not al tered in cLP ILC2 from I l27RA - / - mice
(Supplementary Figure 5A). Interestingly, the potency of
CD127+ CD90.2+ cLP ILC to co-produce IL-13 and IL-5 was
reduced in Stat1-/- but not in Stat4-/- (Supplementary Figure
5B). Overall, STAT1 and STAT4 did not appear to play a critical
role in in controlling the cellularity of the NKp46-negative ILC3
populations and ILC2 in the cLP (Figure 5).DISCUSSION
There is currently no effective drug to cure IBD, and there is an
urgent need to identify novel strategies of treatment. We and
others have identified T-bet to be central to drive the severity of
colitis in human and mice. However, targeting T-bet for instance
using a small molecule inhibitor as has been tested for RORgt
(39, 40) requires more detailed understanding of the functional
role of ILC3 in the absence of T-bet. The relevance of this has
been demonstrated by the protective role of T-bet in Rag-
deficient mice infected with H. thyphlonius (31, 34). These data
indicate that IL-17A+ ILC, which could be ILC3 or inflammatory
ILC2 (41), can drive colitis in the absence of T-bet and adaptive
immune responses, such as regulatory T cells and sIgA, sIgM,
and sIgG production.
In this study, we report that T-bet deficiency results in a very
significantly increased cellularity of NKp46-negative ILC3 in
Rag-deficient and Rag-sufficient naïve mice. Previously, we
reported an approximate 2-fold increase in cLP ILC2 in T-bet-
deficient mice (13). Importantly, greater cellularity of ILC3 in
Tbx21-/- mice correlated with enhanced neutrophilia in Rag-
sufficient Tbx21-/- mice. However, the activation of these
neutrophils was not altered by T-bet-deficiency which might
be due to an intact epithelial barrier preventing microbes to
infiltrate the tissue. Overall, T-bet deficiency caused increased
NKp46- CCR6- ILC3 and ILC2 cellularity in Rag-sufficient mice,
but not at the cost of spontaneous colitis as observed in H.
thyphlonius-infected Rag2-/-xTbx21-/- mice (31, 34).
A study by Klose et al. (2) suggested that NKp46- CCR6- ILC3
may be precursor cells of NKp46+ ILC3 in the intestine.
Considering these data, it may be possible that the
accumulation of NKp46- CCR6- ILC3 in T-bet-deficient mice
is a consequence of the inhibited further differentiation.
Mechanistically, greater cellularity of NKp46- CCR6- ILC3
was correlated to greater expression of IL-7Ra and RORgt in
Rag-sufficient mice. The same effect was not observed in Rag-
deficient mice suggesting that in these mice those factors are
unlikely driving factors of NKp46- ILC3 cellularity in the absence
of T-bet. In contrast to NKp46- CCR6- ILC3, an enhanced
CD127 expression was not observed in CCR6+ ILC3 and ILC2
in Tbx21-deficient mice pointing to an intrinsic T-bet-dependent
CD127 regulation pathway in NKp46- CCR6- ILC3.
Interestingly, we observed that T-bet can bind to the Cd127
gene locus in CD4 T cells which may indicate that T-bet
functions as a repressor of CD127 expression (31, 38). In CD4
T cells, T-bet is known to inhibit transcription of Rorc (encodingFrontiers in Immunology | www.frontiersin.org 9RORgt), and this may be also a critical intrinsic mechanism for
enhanced RORgt expression in Tbx21-deficient NKp46- CCR6-
ILC3 (42). Interestingly, T-bet-dependent regulation of RORgt
and CD127 in NKp46- CCR6- ILC3 was only observed in Rag-
sufficient C57BL/6 and not Rag-deficient BALB/c mice. Despite
of this, T-bet in these Rag-deficient mice regulated cellularity of
NKp46- CCR6- ILC3 and CCR6+ ILC3. These data indicate that
T-bet may regulate the cellularity of NKp46- CCR6- ILC3 via
further mechanisms not controlled by CD127 and RORgt
expression in ILC.
We also aimed to reveal potential further signaling pathways
that enhance T-bet-driven effects in NKp46-negative ILC3 and
ILC2. Both IFNg and IL-27 are known to promote T-bet
expression and at least pulmonary ILC3 have been reported to
express the receptors for both cytokines (43–46), however, we
report here that the deficiency of neither of these mediators and
STAT1 resulted in the enhanced cellularity of NKp46-negative
ILC3 or ILC2. IFNg signals through a STAT1 homodimer,
while a STAT1:STAT3 heterodimer is employed downstream
of the IL-27 receptor (45, 47). Furthermore, STAT4 as an
important signal transmitter downstream of the IL-12 receptor
regulating T-bet expression (48) did not appear to have a crucial
role in the cellularity of NKp46-negative ILC3 and ILC2 as well.
In addition, neither STAT1 nor STAT4 signaling events
appeared to control CD127 and RORgt expression in cLP
NKp46-negative ILC3. Overall, this study suggests that RORgt
and IL-7R are plausible targets of T-bet to limit the cellularity of
NKp46- CCR6- ILC3 and neutrophils in the colonic lamina
propria of immunocompetent mice. This is of critical
importance to evaluate potential side effects of T-bet targeted
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x Tbx21-/- SI LP NKp46- ILC3. ILC were isolated from the SI LP of Rag2-/- and
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Supplementary Figure 4 | Analysis of cLP ILC3 from mice deficient of IFNg, IL-
27Ra, STAT1, or STAT4. cLP ILC3 were isolated for flow cytometry analysis.
NKp46- CCR6- and CCR6+ cLP ILC3 from C57BL/6 and either Ifng-/-, Il27RA-/-,
Stat1-/-, or Stat4-/- mice were analyzed as live CD45+ Lin- CD127+ RORgt+
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representative of a minimum of 3 biological replicates.
Supplementary Figure 5 | cLP ILC2 analysis in Stat1-/- and Stat4-/- mice. cLP ILC
were isolated for flow cytometry analysis. (A) CD127 gMFI expression in live CD45+
Lin- CD127+ ICOS+ KLRG1+ ILC from Stat1-/-, Il27RA-/-, or Stat4-/- mice. (B)
Percentage of IL-13 and IL-5 co-expression in live CD45+ Lin- CD127+ CD90.2+ ILC
from Stat1-/- or Stat4-/- mice. Data shown are representative of 4 biological replicates.REFERENCES
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